Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers release_a6kzna7kmzgjhpsfubgeavdmmu

by Nicholas J. Ashton, Marc Suárez-Calvet, Amanda Heslegrave, Abdul Hye, Cristina Razquin, Pau Pastor, Raquel Sanchez-Valle, José L. Molinuevo, Pieter Jelle Visser, Kaj Blennow, Angela K. Hodges, Henrik Zetterberg

Published in Alzheimer's Research & Therapy by Springer Science and Business Media LLC.

2019   Volume 11, Issue 1, p94

Abstract

Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer's disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia.
In text/plain format

Archived Files and Locations

application/pdf  703.2 kB
file_m734t6l37zc3bnjymh445g3h6u
alzres.biomedcentral.com (web)
web.archive.org (webarchive)
application/pdf  748.4 kB
file_mqc5tnfn6zfjlfid45gxzcxixm
kclpure.kcl.ac.uk (web)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2019-11-28
Language   en ?
Container Metadata
Open Access Publication
In DOAJ
In Keepers Registry
ISSN-L:  1758-9193
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 6210da1e-7dc6-4abb-b78a-b9c59c43fae8
API URL: JSON